Mr. Elad Bibi-Aviv reports

SEEGNAL INC. ESTABLISHES STRATEGIC COMMERCIALIZATION TEAM AND APPOINTS ARX AS INVESTOR RELATIONS ADVISOR

Seegnal Inc. has formed a dedicated strategic commercialization team led by its chief executive officer, and has engaged CapitaLynx Ltd. (operating as Arx) as its investor relations adviser.

Establishment of strategic commercialization team

Seegnal has established a cross-functional strategic commercialization team tasked with accelerating the company's go-to-market execution across target health care systems and geographies. The team is led directly by the chief executive officer and includes senior members, representing clinical affairs, business development, regulatory strategy and technology integration.

The formation of this team reflects the company's transition into a structured commercialization phase following the successful deployment and clinical validation of its medication safety platform at leading health care institutions. The team is responsible for managing strategic partnerships, contract negotiations and revenue-generating deployment pipelines.

"Establishing a dedicated commercialization team is a defining step in Seegnal's evolution from clinical proof of concept to scalable market presence," said Elad Bibi-Aviv, chief executive officer of Seegnal. "We are executing with clarity and urgency, and our team has the operational depth to convert our clinical track record into sustained commercial momentum."

Engagement of Arx as investor relations adviser

Pursuant to TSX Venture Exchange Policy 3.4, Seegnal announces that it has engaged Arx to provide technology-powered investor relations services commencing on April 1, 2026, pursuant to the terms of an investor relations technology and service agreement dated March 26, 2026, between Seegnal and Arx.

The services to be provided by Arx include: press release and investor material drafting and optimization; stock and investor monitoring; third party news wire distribution and reporter targeting; management of an investor relations inbox; and ancillary advisory support relating to capital market and investor relations matters.

The agreement has an initial non-cancellable term of three months, during which the company is required to pay a aggregate fee of $49,500 (U.S.) ($16,500 (U.S.) per month), followed by automatic quarterly renewals at a fee of $16,500 (U.S.) per month ($49,500 (U.S.) per quarter). After the initial term, the agreement shall automatically renew for successive quarterly periods, each consisting of three months, and either party may terminate the agreement by providing no fewer than 30 days prior written notice.

Arx is an arm's-length party to the company. Arx does not currently hold any securities of Seegnal.

About Seegnal Inc.

Seegnal is a global leader in clinical decision support, applying patient-centric medication safety standards to improve outcomes across health care systems. Seegnal's proprietary platform is deployed at leading hospital networks and provides real-time, point-of-care medication safety intelligence.

We seek Safe Harbor.